Cellectis Develops a Cost-effective and State-of-the-art Off-the-shelf CAR T-cell Therapy


Date : Nov 25, 2019 Author : PMR Editorial Staff Category : Healthcare

Cellectis Develops a Cost-effective and State-of-the-art Off-the-shelf CAR T-cell Therapy

A recent off-the-shelf gene-edited CAR T-cell therapy developed by Cellectis, a French Biotech company, could potentially provide solutions to treat solid tumors – a much-needed breakthrough in the CAR T-cell therapies space. Furthermore, the approved Kymriah and Yescarta, CAR T-cell therapies constitute of immune T-cells that are genetically modified and have the capacity to deal with certain types of blood cancer. However, these therapies have not offered effective solutions to treat solid tumors. However, the new CAR T-cell therapy by Cellectis is primarily developed to eliminate the limitations put forward by Kymriah and Yescarta. The newly developed therapy releases an inflammatory protein named IL-12 which plays a key role in assisting the cells to withstand the suppressive effects of the tumor

Further, the new CAR T-cell therapy developed by Cellectis will further overcome the limitations of several other existing therapies. At present, T-cells for all therapies are collected from the patients before the modification stage – a process that involves high transportation and manufacturing costs. However, the new off-the-shelf gene therapy is predominantly designed to enable companies to store cells from the donors and utilize them when required

Similar to Cellectis, several other companies have taken a similar route in developing off-the-shelf CAR T-cell therapies to fight solid tumors. For instance, Celyad, a Belgian biotech company recently published the results of the first-ever clinical CAR T-cell therapy used to treat patients with colorectal cancer. In addition, the treatment introduced by Celyad is aimed at dealing with solid tumors by modifying the T-cells with certain variants of proteins. Several pharmaceutical companies have upped their interest in developing advanced CAR T-cell therapies and break the barriers put forward by the existing therapies.

In recent years, healthcare professionals have identified CAR T-cell therapy as one of the most preferred treatments for patients who have stopped responding to the alternative treatments that are available. Moreover, CAR T-cell therapy is gradually gaining significant attention owing to the increased rate of cancer remission exhibited by the treatment. In addition, patient compliance continues to remain a vital factor while opting for a treatment and as CAR T-cell therapy does not require multiple visits to a healthcare facility, it has garnered significant attention in recent years – a trend that is likely to continue in the upcoming years.

Over the past few years, an exponential rise in the number of cancer cases worldwide has intensified the race towards discovering effective and concrete therapeutic solutions. Further, according to multiple studies, in the current scenario, nearly 1.7 million cancer patients and 4.3 million cancer patients are present in the U.S. and China respectively. Further, studies also suggest that around 61,780 new leukemia cases, 82,310 new lymphoma cases, and 32,110 new myeloma cases are expected to register in the U.S. in 2019. Thus, as these numbers keep ascending at a rapid pace, investments towards the research of CAR T-cell therapies have also increased. Although traditional treatments such as radiation and chemotherapy continue to remain popular, the advent of immunotherapies such as CAR T-cell therapy has redefined cancer treatment. CAR T-cell therapy has emerged as one of the most recent immunotherapies to treat cancer and is likely to gain significant traction in the upcoming years. Furthermore, as more and more companies continue to invest in R&D activities to improve the output of their new-age CAR T-cell therapies, the CAR T-cell therapy market is expected to witness steady growth in the upcoming years. According to the latest study published by Persistence Market Research, CAR T-cell therapy is expected to grow at a CAGR of ~18% during the forecast period (2019-2026).  


Back To Top